MedPage Today - GLP-1, TZD Combo May Cut Heart Risk - Kristina Fiore

New York, NY
 – October 9, 2013  –– 

The GLP-1 agonist exenatide (Byetta, Bydureon) may temper the cardiovascular risks associated with rosiglitazone (Avandia), possibly via its effects on a clotting pathway, researchers from the Icahn School of Medicine at Mount Sinai reported in Science Translational Medicine. An analysis of data from the FDA's Adverse Event Reporting System (AERS) revealed a significantly lower percentage of myocardial infarction (MI) reports among patients taking rosiglitazone plus exenatide, compared with those on rosiglitazone alone, according to Ravi Iyengar, PhD, Director of Experimental Therapeutics at the Icahn School of Medicine at Mount Sinai. "Many times when people take two drugs, they have unanticipated beneficial effects, and when things go well, no one complains," Dr. Iyengar told MedPage Today. "So these beneficial effects typically go unnoticed, and it's the data-mining of these big databases that allows us to see them."
-Dr. Ravi Iyengar, Professor, Oncological Sciences, Psychiatry, Pharmacology and Systems Therapeutics, Director, Experimental Therapeutics, Icahn School of Medicine at Mount Sinai
Learn more, including video with Dr. Iyengar

Additional coverage: